Relapse · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants experiencing at least one relapse compared with interferon beta 1a (low certainty).
1 finding from 1 review
Number of participants whose disability worsened · patients with relapsing‐remitting multiple sclerosis
Alemtuzumab 24 mg may leads to lower number of participants whose disability worsened compared with interferon beta 1a (low certainty).
1 finding from 1 review
Intervention not reported
Very preterm birth (less than 34 weeks) ‐ assuming complete correlation between twins/triplets · women with multiple pregnancy
The intervention showed no clear difference in very preterm birth (less than 34 weeks) ‐ assuming complete… (low certainty).
1 finding from 1 review
Intervention not reported
Prelabour preterm rupture of the membrane · women with multiple pregnancy
The intervention showed no clear difference in prelabour preterm rupture of the membrane (low certainty).
1 finding from 1 review
Intervention not reported
Small‐for‐gestational age ‐ assuming independence between twins · women with multiple pregnancy
The intervention showed no clear difference in small‐for‐gestational age ‐ assuming independence between twins (low certainty).
1 finding from 1 review
Intervention not reported
Psychosocial effects of bed rest (depression, anxiety, stress) · women with multiple pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Perinatal mortality ‐ assuming independence between twins/triplets · women with multiple pregnancy
The intervention showed no clear difference in perinatal mortality ‐ assuming independence between twins/triplets (low certainty).
1 finding from 1 review
Intervention not reported
Low birthweight (less than 2500 g) ‐ assuming independence between twins/triplets · women with multiple pregnancy
The intervention showed no clear difference in low birthweight (less than 2500 g) ‐ assuming independence between… (low certainty).
1 finding from 1 review
Intervention not reported
Prelabour preterm rupture of the membrane · women with multiple pregnancy
The intervention showed no clear difference in prelabour preterm rupture of the membrane (low certainty).
1 finding from 1 review
Intervention not reported
Small‐for‐gestational age ‐ assuming independence between twins/triplets · women with multiple pregnancy
The intervention showed no clear difference in small‐for‐gestational age ‐ assuming independence between… (low certainty).
1 finding from 1 review
Intervention not reported
Psychosocial effects of bed rest (depression, anxiety, stress) · women with multiple pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Very preterm birth (less than 34 weeks) ‐ assuming complete correlation between twins · women with multiple pregnancy
The intervention showed no clear difference in very preterm birth (less than 34 weeks) ‐ assuming complete… (low certainty).
1 finding from 1 review
Intervention not reported
Perinatal mortality ‐ assuming independence between twins · women with multiple pregnancy
The intervention showed no clear difference in perinatal mortality ‐ assuming independence between twins (low certainty).
1 finding from 1 review
Intervention not reported
Low birthweight (less than 2500 g) ‐ assuming independence between twins/triplets · women with multiple pregnancy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with relapse Risk ratio (M‐H, random, 95% CI) compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Number of participants with confirmed progression Risk ratio (M‐H, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants with confirmed progression Risk ratio (M‐H,… compared with glatiramer acetate (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with relapsing‐remitting multiple sclerosis
Interferons showed no clear difference in number of participants who dropped out for AEs Risk ratio (M‐H,… compared with glatiramer acetate (low certainty).
1 finding from 1 review
Mean number of active T2 lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean number of new enhancing lesions Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review
Mean change in total T2‐hyperintense lesion load Mean difference (IV, random, 95% CI) · patients with relapsing‐remitting multiple sclerosis
1 finding from 1 review